One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

In an interview with Fortune, Isomorphic Labs president Colin Murdoch shared that four years after its founding, the company ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...

Out to make a bigger difference, Alphabet’s Isomorphic Labs is exploring a much more useful application of AI. The Google ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.

Isomorphic Labs advances towards human clinical trials for AI-designed drugs, marking a pivotal moment in pharmaceutical ...